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Abstract Synucleins are a family of small proteins that are
predominantly expressed in neurons. The functions of the
synucleins are not entirely understood, but they have been
implicated in the pathogenesis of several neurodegenerative
diseases. Our data show that K-, L- or Q-synuclein suppresses
the aggregation of thermally denatured alcohol dehydrogenase
and chemically denatured insulin. The A53T but not the A30P
mutant K-synuclein was able to inhibit the aggregation of insulin
and the chaperone-like activity of K-synuclein was lost upon
removal of its C-terminal residues 98^140. These results
demonstrate that synucleins with the exception of the A30P
mutant possess chaperone-like activity.
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1. Introduction
The human synuclein family includes four homologous pro-
teins, K-, L- and Q-synuclein and synoretin [1^5]. Synucleins
are highly soluble proteins with unknown function and di¡er-
ent expression pro¢les. The K- and L-synucleins are predom-
inantly pre-synaptic proteins expressed in neurons of the cen-
tral nervous system [1^5]. Q-Synuclein is di¡usely distributed
in the cytoplasm of peripheral neurons, although it is also
expressed in the brain [4], while synoretin, which is also found
in the brain, is expressed at high levels in the retina [5]. Mu-
tations in the K-synuclein gene (A53T and A30P) have been
linked to familial Parkinson’s disease (PD)[6^8]. More impor-
tantly, wild type K-synuclein is the major component of Lewy
bodies (LBs) in sporadic PD, dementia with LBs (DLB) and
in a subtype of Alzheimer’s disease known as the LB variant
of Alzheimer’s disease [9^11]. Wild type K-synuclein is also a
major component of neuronal and glial cytoplasmic inclusions
in multiple system atrophy [9^11] and the K-synuclein peptide
(residues 61^95) known as the non-amyloid component of
plaques has been implicated in amyloidogenesis in Alzheimer’s
disease [12,13]. Moreover, antibodies against L-synuclein re-
vealed novel staining of degenerating mossy ¢ber terminals in
the dentate gyrus, the hilar and CA2/3 regions of the hippo-
campus while antibodies against Q-synuclein stain axonal
spheroid-like lesions in the hippocampal region in PD and
DLB patients [14]. These new ¢ndings suggest that not only
K-synuclein but also L- and Q-synuclein may be involved in the
pathogenic mechanism responsible for the onset and progres-
sion of PD and DLB.
K-Synuclein, the most extensively studied synuclein, is a
small acidic protein consisting of 140 amino acids [1]. The
circular dichroism spectra of wild type K-synuclein is a typical
spectrum of type U (main feature a negative band at 199 nm),
which in water is characteristic of an unordered structure in
equilibrium with reverse turns [15^17]. K-Synuclein protein
contains as little as 3% K-helices and 23% L-sheets and poly-
merizes to ¢brils in vitro [15,16,18]. The formation of poly-
mers is accompanied by an increase in anti-parallel L-sheet
conformation and is accelerated by the two known mutations
[15,16,18]. Wild type K-synuclein binds to small (hydrodynam-
ic diameter of 20^30 nm) unilamellar vesicles in vitro [17]. The
binding of K-synuclein to vesicles is associated with a signi¢-
cant increase in K-helical conformation [17]. The A30P mu-
tant has reduced a⁄nity for vesicles [19]. In addition K-synu-
clein has been shown to associate with a number of proteins.
The association with phospholipase D2 inhibits phospholipase
D2 function [20] whereas the association of the K-synuclein
with synphilin-1 promotes the formation of cytoplasmic inclu-
sions [21]. The N-terminal portion of K-synuclein (residue 1^
61) shares 40% amino acid homology with the family of 14-3-
3 proteins [22]. 14-3-3 proteins, like synucleins, are ubiqui-
tously expressed in the brain and have been shown to asso-
ciate in a chaperone-like manner with PKC, BAD, ERK and
Raf-1 [22,23]. K-Synuclein binds to 14-3-3 as well as to PKC,
BAD, ERK and the microtubule associated protein tau, but
not Raf-1 [22,24]. The interaction of K-synuclein with proteins
has led us to hypothesize that synucleins may be functioning
as molecular chaperones. This possibility was evaluated in two
well-established assays, the thermal-induced aggregation of
alcohol dehydrogenase (ADH) and the chemical-induced ag-
gregation of insulin.
2. Materials and methods
2.1. Puri¢cation of synuclein proteins
Human K-, L- and Q-synuclein and the A30P and A53T K-synuclein
mutant were subcloned into the bacterial expression vector pRK172
and were expressed in Escherichia coli BL21 and puri¢ed as described
previously [18]. The protein concentration was determined using the
bicinchoninic acid protein assay (Pierce) using bovine serum albumin
as a standard.
2.2. Chaperone-like activity assays
Recombinant human heat shock protein (HSP) 27 was from Stress-
gen (Victoria, B.C., Canada). Bovine insulin, horse liver ADH and
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bovine pancreatic ribonuclease A (RNAse A) were from Sigma, St.
Louis, MO, USA. The following molecular masses for insulin, ADH,
K-synuclein, L-synuclein and Q-synuclein, HSP27 and bovine RNAse
A were utilized to determine the molar concentration of proteins: 5.7,
80, 14.4, 14.3, 13.3, 22.3 and 13.7 kDa, respectively. The thermal-
induced aggregation of horse liver ADH was performed as described
previously [25]. ADH, 0.5 mg/ml (6.2 WM), was dissolved in 50 mM
phosphate bu¡er, pH 7.0, and the protein was heated at 45‡C. The
thermally denatured ADH in the absence of a chaperone aggregates
over time. The aggregation of ADH is monitored by the increase in
light scattering at 360 nm in a microplate spectrophotometer (Molec-
ular Devices Corporation, Sunnyvale, CA, USA). The e¡ect of synu-
cleins was determined by the addition of di¡erent amounts of synu-
cleins.
Bovine insulin dissolved in 20 mM NaOH was diluted in 100 mM
phosphate bu¡er, pH 7.0, to a ¢nal concentration of 0.15 mg/ml
(26 WM). Insulin was reduced as described previously [26] by the
addition of 20 mM DTT. The extent of aggregation of the insulin B
chain after reduction was determined as a function of time at 25‡C by
monitoring the scattering at 360 nm. Each concentration of synucleins
was repeated in triplicate for both chaperone activity assays.
2.3. Preparation of truncated K-synuclein
K-Synuclein (5 mg/ml) was digested with 5 Wg/ml endoproteinase
Asp-N from Pseudomonas fragi (Calbiochem, CA, USA) in 50 mM
potassium phosphate bu¡er, pH 7.0, overnight at 37‡C. The reaction
was stopped by the addition of 0.1 mg/ml of leupeptin. The protein
was then separated on a 16.5% sodium dodecyl sulfate (SDS)^poly-
acrylamide gel and visualized by Coomassie blue R-250.
3. Results and discussion
The chaperone-like activity of synucleins was determined by
their ability to prevent the thermally-induced aggregation of
ADH at 45‡C and the chemically-induced aggregation of in-
sulin at 25‡C. These two assays have been extensively utilized
to determine the chaperone-like activities of proteins [25^29].
Heating of ADH at 45‡C denatures the protein and induces
aggregation, which is followed over time at 360 nm (Fig. 1).
The addition of puri¢ed human K-synuclein to the denatured
protein solution reduced the aggregation of ADH (Fig. 1A). A
three-fold molar excess of K-synuclein was required for a 50%
reduction in the aggregation of ADH whereas a six-fold molar
excess of K-synuclein resulted in more than 70% reduction in
aggregation (Fig. 1A). Similar to K-synuclein, L- and Q-synu-
cleins are equally e¡ective in abrogating this aggregation (not
shown). Under the same conditions, human heat shock pro-
tein HSP27 with a known chaperone-like activity was capable
of reducing the aggregation of ADH (Fig. 1B). In contrast
bovine RNAse A, which is similar in size to the synucleins
and does not possess chaperone-like activity, was not able to
reduce the aggregation of ADH (Fig. 1C).
Reduction of the disul¢de bonds between the A and B
chains of insulin with DTT leads to the aggregation of B
chains. In the absence of a chaperone, the aggregation of
the denatured B chains is monitored over time by the increase
in light scattering at 360 nm (Fig. 2). The addition of puri¢ed
human K-synuclein resulted in a reduction of insulin aggrega-
tion (Fig. 2A). A two-fold molar excess of synucleins was
required to suppress the aggregation of insulin by more
than 50% (Fig. 2A). Both L- and Q-synucleins were capable
of preventing the aggregation of insulin (not shown). Two
point mutations of K-synuclein linked to familial PD
(Ala30CPro and Ala53CThr) were also assayed for their
ability to suppress the DTT-induced aggregation of insulin.
The A53T mutant K-synuclein was capable of preventing the
aggregation of insulin similar to the wild type K-synuclein
(Fig. 2B). In contrast, the A30P mutant K-synuclein did not
suppress the aggregation of DTT-treated insulin B chains
(Fig. 2B). The same results were obtained using the ADH
thermal-induced aggregation assay (data not shown). The
A30P mutant protein has been found incapable of binding
vesicles [19] whereas the A53T mutant protein was found to
form K-synuclein polymers faster than wild type and A30P
mutant proteins [15,17,18] and showed an increased interac-
tion with synphilin-1 [21]. The data herein indicate that the
A30P mutant is also incapable of chaperone-like association
with denatured proteins and suggests that the A30P mutant
may promote the formation of protein polymers by associa-
tion with aggregation-prone proteins. HSP27 but not RNAase
A were able to reduce the aggregation of insulin (Fig. 2C^D).
A unique feature of chaperone proteins is a £exible hydro-
philic tail region in the C-terminal. Nuclear magnetic reso-
nance spectroscopy has revealed that proteins with chaper-
one-like activities, such as K-crystallin and HSP25, have
unstructured £exible solvent-exposed C-terminal extensions
[27,28]. The polar and £exible C-terminal tail is thought to
promote the interaction of the chaperone with the hydropho-
bic region in the denatured protein and thus play a critical
role in substrate^chaperone association [27,28]. The mutation
Fig. 1. Chaperone-like activity of K-synuclein assessed by the ADH
assay. A: The reduction in the aggregation of ADH (6.2 WM) in
50 mM phosphate bu¡er, pH 7.0, at 45‡C is shown as a function of
time in the absence or presence of di¡erent concentrations of K-syn-
uclein. Lines 1^4: 0, 3.5, 17.5 and 35 WM K-synuclein, respectively.
B: Thermal aggregation of ADH (6.2 WM) in the presence of
HSP27. Lines 1^6: 0, 0.024, 0.060, 0.120, 0.24 and 0.72 WM HSP27,
respectively. C: Thermal aggregation of ADH (6.2 WM) in the pres-
ence of 0, 3.5, 7.0, 27.6 and 55 WM RNAse. Each concentration of
protein was repeated in triplicate and a representative tracing is
shown.
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or deletion of 17 residues from the C-terminal of K-crystallin
caused a marked reduction in the chaperone-like activity of
this protein [27]. The C-terminal of the synuclein proteins is
rich in aspartic and glutamic acid residues similar to proteins
with chaperone-like activity such as tubulin and the mitochon-
drial chaperonin CNP60 protein. The £exible negatively-
charged C-terminal of tubulin was recently found to be critical
for the ability of this protein to interact with other proteins in
a chaperone-like fashion [29]. To test if the C-terminal of
K-synuclein is required for the chaperone-like activity, K-syn-
uclein was digested with endoproteinase Asp-N. Endoprotein-
ase Asp-N has been shown to cleave the aspartic residues in
K-synuclein [30] leading to a truncated protein corresponding
to residues 2^97, with a predicted molecular mass of 9.5 kDa
(Fig. 3A). The data in Fig. 3B indicate that truncated K-syn-
uclein (2^97) does not possess a chaperone-like activity sug-
gesting that the C-terminal of K-synuclein plays a role in
conferring this activity. The highly-charged C-terminal of
K-synuclein may be important for maintaining its solubility
since K-synuclein with a truncated C-terminal (i.e. deletion
of residues 110^140 or 120^140) was found to aggregate faster
than full-length K-synuclein under the same conditions [31].
Thus, it is possible that the truncated (2^97) K-synuclein in-
teracts with the hydrophobic exposed region of insulin or
ADH but the complexes may not be stable or water soluble
as the C-terminal of K-synuclein may be required in order to
maintain the solubility of the protein and, potentially, the
protein complexes.
Both K-synuclein and a central hydrophobic peptide there-
of, termed NAC, have been shown to aggregate alone and
with other amyloidogenic proteins to form ¢brils. The NAC
peptide, although natively unfolded, is predicted to form a
L-sheet structure that promotes self-aggregation, binding to
amyloid and the formation of amyloid ¢brils [17,32]. The
interaction of the NAC region of K-synuclein with synphi-
lin-1 appears to facilitate the formation of cellular inclusions
[21]. Moreover, overexpression of K-synuclein in dividing cells
may increase their susceptibility to environmental aversion,
which may be due to its interaction with BAD, ERKs or other
proteins involved in signal transduction [22]. Therefore the
interaction of the NAC peptide or even of full-length K-syn-
uclein with some ‘inappropriate’ protein partner as a result of
overexpression may be detrimental to cell viability. However,
protein^protein interaction of K-synuclein requiring the C-ter-
minal may be bene¢cial since this association produces stable
water-soluble complexes with denatured proteins. Although
the data herein support a chaperone-like function for the syn-
ucleins it remains unknown if the synucleins retain this activ-
ity in vivo.
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